Gelteq Limited (GELS)
GELS trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of October 14, 2026. Revenue: SEC 20-F (ifrs-full:RevenueFromContractsWithCustomers), period ending 2025-06-30, https://www.sec.gov/Archives/edgar/data/1920092/000121390025111090/0001213900-25-111090-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), period ending 2025-06-30. Converted from AUD at 1.4266 per USD (ECB reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | GELS on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Australia |
| IPO year | 2024 |
| SEC CIK | 0001920092 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | C3 |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $116K |
| Net income | -$6.6M |
| Operating income | Not in SEC XBRL data |
| Net margin | -5723.4% |
| Operating margin | Operating income not reported |
| Revenue growth | No prior-year revenue to compare |
| Cash | Not in SEC XBRL data |
| Total assets | Not in SEC XBRL data |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 44.3× |
Reported in AUD; shown in US dollars.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document PROSPECTUS | 424B3 | 2025-08-29 |
| Latest annual report ANNUAL REPORT | 20-F | 2025-11-17 |
| Latest quarterly / interim REPORT OF FOREIGN PRIVATE ISSUER | 6-K | 2026-07-06 |
Source: SEC EDGAR submissions feed, 71 recent filings. All filings on EDGAR.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| ADXN | Addex Therapeutics Ltd | $3.01 | -0.99% | $5.1M |
| PULM | Pulmatrix Inc. | $1.38 | -3.50% | $5.0M |
| KALA | KALA BIO Inc. | $0.2600 | -7.14% | $5.0M |
| SCNX | Scienture Holdings Inc. | $3.24 | -17.14% | $5.3M |
| PCSA | Processa Pharmaceuticals Inc. | $1.77 | -6.84% | $5.0M |
| XBIO | Xenetic Biosciences Inc. | $2.10 | -0.94% | $4.9M |
| XTLB | XTL Biopharmaceuticals Ltd. | $1.98 | +3.12% | $4.9M |
| LNAI | Lunai Bioworks Inc. | $1.03 | -7.21% | $4.7M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier